ACAlejandro Costaguta

Alejandro Costaguta

*This is an algorithmically generated author record based on publicly available information.

Alejandro Costaguta has a total of 54 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Biliary Atresia: advances and challenges in early diagnosis and management

    by Elisa de Carvalho, Mirta Elba Ciocca, Gilda Porta, Natascha Silva Sandy, Carlos Marcelo Timossi, Marcela Godoy, Carola López, Michelle Higuera, Irene Miura, Themis Reverbel Silveira, et al.


  • Open Access

    Autoimmune hepatitis: Towards a personalized treatment

    by Alejandro Costaguta, Guillermo Costaguta, Fernando Álvarez

    Autoimmune hepatitis is an uncommon condition that affects both adults and children and is characterized by chronic and recurrent inflammatory activity in the liver. This inflammation is accompanied by elevated IgG and autoantibody levels. Historically, treatment consists of steroids with the addition of azathioprine, which results in remission in approximately 80% of patients. Despite significant advancements in our understanding of the immune system over the past two decades, few modifications have been made to treatment algorithms, which have remained largely unchanged since they were first proposed more than 40 years ago. This review summarized the various treatment options currently available as well as our experiences using them. Although steroids are the standard treatment for induction therapy, other medications may be considered. Cyclosporin A, a calcineurin inhibitor that decreases T cell activation, has proven effective for induction of remission, but its long-term side effects limit its appeal for maintenance. Tacrolimus, a drug belonging to the same family, has been used in patients with refractory diseases with fewer side effects. Sirolimus and everolimus have interesting effects on regulatory T cell populations and may become viable options in the future. Mycophenolate mofetil is not effective for induction but is a valid alternative for patients who are intolerant to azathioprine. B cell-depleting drugs, such as rituximab and belimumab, have been successfully used in refractory cases and are useful in both the short and long term. Other promising treatments include anti-tumor necrosis factors, Janus kinases inhibitors, and chimeric antigen receptor T cell therapy. This growing armamentarium allows us to imagine a more tailored approach to the treatment of autoimmune hepatitis in the near future.


  • Open Access

    Influence of Information Access on Organ Donation: A Questionnaire-Based Cross-Sectional Study

    by Guillermo A. Costaguta, Andrea Romero, Alejandro C. Costaguta

    Introduction Organ transplantation is the sole effective treatment for end-stage organ diseases. However, the availability of donor organs remains insufficient. This shortage is driven by several factors, with access to accurate information being the key determinant of an individual’s willingness to donate organs. Methods A cross-sectional study based on anonymous surveys conducted from January to December 2019, categorizing participants into healthcare professionals and non-healthcare individuals. Data included willingness to donate organs, reasons for refusal, age, education level, and understanding of brain death. Statistical significance was set at pResults A total of 408 participants were included: 203 in the healthcare sector and 205 in the non-healthcare sector. Among healthcare professionals, 90% were willing to donate organs compared to 43% in the non-healthcare group (pConclusion Healthcare professionals are more inclined to be organ donors than are those outside the field. Misunderstandings among non-healthcare individuals contributed to higher refusal rates. Tailored awareness campaigns and educational programs could rectify these misconceptions, potentially improving donation rates and mitigating organ shortage crises.

  • Lack of differences in outcomes between 3 immunosuppression protocols in the first year after pediatric liver transplantation: A multicenter study

    by Alejandro C. Costaguta, Guillermo A. Costaguta, Carolina Rumbo, Gabriel Gondolesi, Daniel D’aGostino, María Belén Pallitto, Oscar Bottasso, Fernando Álvarez

    Introduction: Advances in immunosuppression have extended patient and graft survival rates after solid organ transplantation; however, this is not free of side effects. Balancing safety and efficacy is of paramount importance, particularly in the pediatric setting. Current literature comparing different protocols is scarce, and decisions are mostly guided by physician preference. We aimed to compare three different protocols from four different centers to identify differences in outcomes after one year of follow-up. Materials and methods: A retrospective analysis of the databases of the participating centers was performed. Consecutive patients aged Results: After one year of follow-up, no differences in patient or graft survival were observed when comparing either the entire group (n=97) or patients with biliary atresia only (n=48). The frequencies of rejection and episodes of infection were similar. Renal function showed no differences either before or after transplantation or between the groups. Conclusion: Immunosuppression protocols used in this study appeared to be equally safe and effective. This could offer the opportunity to tailor them to the patient’s individual characteristics without compromising the outcome. Export


  • Guías para el diagnóstico y seguimiento de niños y adolescentes portadores de hipertensión portal

    by Alejandro Costaguta, Paula Borobia, Daniel D'Agostino, Silvia Morise, Rosana Solis, Sandra Pochettino, Graciela Saieg, Cristina Arregui, Carol Lezama, Gustavo Boldrini

    Portal hypertension is a complex syndrome caused by increased resistance to the splachnic venous flow at the portal vein level, with a hyperdynamicsystemic circulation characterized by peripheral vasodilation and high cardiac output. Portal flow can be obstructed at prehepatic ("normal liver"), intrahepatic (as in cirrhosis), or post-hepatic level (as in Budd-Chiari syndrome). In pediatric patients, prehepatic and intrahepatic causesare almost equally distributed (nearly 50% each). Clinical presentation and individual impact are heterogeneous, but in each case, itis the expression of a worsening condition and the need to solve the problem, either by treating its consequences or (ideally) its causes.


  • Open Access

    Embarazo en una adolescente con cirrosis e hipertensión portal: prevención de la hemorragia por várices esofágicas

    by Alejandro Costaguta, Walter Araujo, Sergio Plaza, Pablo Candarle, Soledad Albornoz

    El embarazo en pacientes con cirrosis e hipertensión portal es un escenario con alto riesgo de complicaciones tanto para la madre como para el feto. Entre ellas, el sangrado por várices esofágicas es una de las más temidas. La disponibilidad de tratamientos efectivos puede reducir este riesgo, por lo que la profilaxis primaria debería ser analizada en estas pacientes. Presentamos el caso de una adolescente embarazada con historia de hipertensión portal secundaria a cirrosis hepática por colangitis esclerosante primaria, en quien se realizó prevención primaria del sangrado por várices esofágicas con tratamiento endoscópico, logrando un embarazo y parto a término, sin complicaciones.

  • Open Access

    Ileítis terminal por Yersinia enterocolitica: diagnóstico diferencial con la enfermedad de Crohn en un varón de 12 años

    by Stefanía Cian, Omar Tabacco, Alejandro Costaguta

    Yersinia enterocolitica is a gram-negative rod causing intestinal infection in humans. It shows different clinical pictures with many different etiologies to be ruled-out, which sometimes makes it difficult to reach a timely and correct diagnosis. We report the case of an adolescent boy presenting with right lower quadrant pain from terminal ileitis with endoscopic findings akin to Crohn´s disease finally diagnosed as Yersinia enterocolitica, highlighting the usefulness of the different ancillary methods employed.


  • Open Access

    El nuevo paradigma de la hemocromatosis neonatal: hepatitis fetal aloinmunitaria

    by Alejandro Costaguta

    The classical model of neonatal hemochromatosis was based on the analogy with hereditary hemochromatosis. Medical treatment consisted on the antioxidant-chelator cocktail. The new hypothesis of an alloimmune origin of the process by which the pregnant woman mounts an IgG-based destructive response against fetal hepatocytes offers a pathogenic explanation, allowing treatment to be focused on the immunological aspects, with excellent results, and opens the possibility of preventive treatment in future pregnancies. This new paradigm produces a deep impact in diagnosis, prognosis and treatment of the disease, that should be called "fetal alloimmune hepatitis".